<div><div></div><div><span><p><strong><span>Passage Bio reported updated upliFT-D interim data showing reduced brain atrophy and stabilized plasma NfL with PBFT02.</span></strong></p><span> </span><p><strong><span>Key Highlights:</span></strong></p><span> </span><ul><li><span>PBFT02 CDR‑1 patients showed 3.1% whole brain atrophy at 12m vs 8.7% in ALLFTD NH (64% reduction; n=2 vs n=7).</span></li><li><span>PBFT02 CDR‑1 patients showed 4.6% frontotemporal atrophy at 12m vs 9.9% in ALLFTD NH (54% reduction; n=2 vs n=7).</span></li><li><span>Plasma NfL stabilized in treated patients: mean −1.0 pg/mL at 12m (n=6) vs +13.5 pg/mL in ALLFTD natural history (n=7).</span></li><li><span>Dose 1 (4.5e13 GC) produced durable CSF progranulin increases to mean 22.8 ng/mL at 12m (n=6) and 24.2 ng/mL at 18m (n=3); Dose 2 showed comparable levels by 6m.</span></li><li><span>FDA Type C meeting: agency indicated a randomized controlled registrational study will be required; company is evaluating next steps and initiated a strategic review with Wedbush PacGrow engaged.</span></li></ul><p><span>Original SEC Filing: </span>Passage BIO, Inc. [ PASG ] - 8-K - Apr. 20, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

PASG

LABU

IBBQ

SBIO

<p>Passage Bio reported interim data from its upliFT-D study, showing significant reductions in brain atrophy and stabilization of plasma NfL levels with PBFT02. CDR-1 patients experienced a 64% reduction in whole brain atrophy and a 54% reduction in frontotemporal atrophy at 12 months. The FDA indicated that a randomized controlled registrational study is necessary, prompting the company to evaluate next steps and engage in a strategic review with Wedbush PacGrow.</p>

TradingView

Passage Bio

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Passage Bio reports biomarker improvements, FDA says randomized registrational trial required